Mariko Mimura is an Of Counsel of Nishimura & Asahi. She rejoined Nishimura & Asahi in 2018 and serves as leading counsel for the Life Science and Healthcare practice group of N&A.
Before rejoining N&A, she was the Vice President, General Counsel and Board Member of GlaxoSmithKline K.K., leading Legal, Compliance, Government Affairs, Public Policy and Patient Advocacy from 2015.
From 2010 to 2015, she was a Director, Country General Counsel, and the Head of Legal/Intellectual Property Department, at Novartis Holding Japan K.K., and has managed the legal affairs and IP of all the Novartis Group Companies in Japan, including Novartis Pharma K.K. Her responsibilities as an in-house counsel in the Novartis Group spanned a wide array of work, from general corporate legal affairs to M&A and IP litigation.
She held tenure as a Corporate Officer and General Counsel at GE Healthcare Japan Corporation (manufacture and sale of medical devices and Bio products) from 2005 to 2009, taking on responsibility for legal affairs, IP and compliance across the board. She has also assumed the position of General Counsel of Asia Pacific to oversee legal affairs and compliance in the APAC region. Furthermore, Mariko was appointed as an outside statutory auditor at Nihon Medi-Physics Co., Ltd. (manufacture and sale of pharmaceutical products), an affiliate of GE Healthcare Japan, continuing to hold the position until she left GE Group in 2009.
Following registration with the Japanese Bar Association in 1992, Mariko joined Nishimura & Partners (currently Nishimura & Asahi) in 1995, with expertise in intellectual property, entertainment, general corporate, bankruptcy, and civil rehabilitation. During her tenure at Nishimura & Partners, she was seconded to Gibson, Dunn & Crutcher LLP, a US law firm, as well as working at a US medical device company as Vice President & General Counsel. After returning to Nishimura & Partners, she became a partner in 2003 and served until she became an in-house counsel of GE Healthcare Japan Corporation until 2005.
Thus, she is an in-house counsel pioneer in the Japanese healthcare industry. She was selected as one of the top 100 Corporate Counsel in Asia Pacific in the GC Powerlist of the Legal 500 in 2014.
In 2019, she received an award as a Corporate and M&A lawyer by Best Lawyers® 10th Edition of The Best Lawyers in Japan (2020).